MGX
NASDAQ · Biotechnology
Metagenomi Therapeutics Inc
$0.79
+0.09 (+13.00%)
Financial Highlights (FY 2026)
Revenue
23.10M
Net Income
-80,495,156
Gross Margin
—
Profit Margin
-348.5%
Rev Growth
+13.6%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | — | 47.7% | 47.7% |
| Operating Margin | -380.8% | -342.8% | -27.4% | -26.1% |
| Profit Margin | -348.5% | -331.1% | -30.1% | -22.8% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 23.10M | 20.33M | 24.43M | 24.83M |
| Gross Profit | — | — | 11.64M | 11.84M |
| Operating Income | -87,961,561 | -69,693,991 | -6,693,056 | -6,481,215 |
| Net Income | -80,495,156 | -63,778,185 | -7,358,364 | -5,671,741 |
| Gross Margin | — | — | 47.7% | 47.7% |
| Operating Margin | -380.8% | -342.8% | -27.4% | -26.1% |
| Profit Margin | -348.5% | -331.1% | -30.1% | -22.8% |
| Rev Growth | +13.6% | +13.6% | -4.6% | +12.3% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 7.97M | 8.62M |
| Total Equity | — | — | 19.49M | 21.00M |
| D/E Ratio | — | — | 0.41 | 0.41 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -83,085,279 | -69,487,644 | -8,749,975 | -9,471,019 |
| Free Cash Flow | — | — | -5,557,893 | -4,395,902 |